News

GRP named a top economic development organization in the U.S.

RICHMOND, VA – The Greater Richmond Partnership (GRP) was named among the top 20 economic development organizations in the nation according to Site Selection magazine, a national publication targeting site location professionals and corporate executives making relocation decisions.

The 2022 Mac Conway Awards for Excellence in Economic Development, named in honor of Site Selection founding publisher H. McKinley ‘Mac’ Conway, are awarded annually to the top economic development organizations in the country determined by an index of corporate job creation and facility-related capital investment data calculated both cumulatively and per capita. This marks the first time since 2015 the publication has recognized GRP for outstanding work in its field. It was named a top organization four previous years plus two honorable mentions since its inception in 1994.

“In the last two years, we’ve done a lot of work to come out of the pandemic as a stronger and more focused region and organization. This includes benchmarking best of class regions and regional groups,” said Jennifer Wakefield, President and CEO of GRP. “We are thrilled to be recognized among the best economic development organizations in the country yet again. It’s a testament to our strong public-private partnership and the collaboration found throughout the region to bring jobs and investment to Greater Richmond.”

Earlier this year, Site Selection ranked Greater Richmond as the 3rd top metro for economic development projects per capita for 2021.

Read more here.

Recent News

07/15/2026

Focused Ultrasound Foundation Chairman Receives Lifetime Impact Award

Neal F. Kassell, MD, founder and chairman of the Focused Ultrasound Foundation, received the inaugural Lifetime Impact Award at the 2026 annual meeting of the International Society for Therapeutic Ultrasound (ISTU) in Norway in June. The award honors individuals whose work has fundamentally shaped the development, adoption, and global impact of focused ultrasound. “Dr. Kassell’s

07/14/2026

ARPA-H awards up to $160 million to advance personalized curative medicines for rare genetic diseases

The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, today announced the teams for the Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE) program — a critical investment toward bringing new treatments to patients faster and cure rare genetic pediatric diseases. THRIVE

07/09/2026

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for QRX003 for the treatment of Peeling Skin Syndrome (PSS), enabling initiation of its planned Phase 2 clinical study. Quoin